Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Decreases By 38.6%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 6,068 shares, a decrease of 38.6% from the April 30th total of 9,883 shares. Based on an average daily volume of 5,229 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.0% of the company’s shares are short sold.

Molecular Partners Stock Down 3.1%

Molecular Partners stock opened at $3.91 on Friday. The business has a fifty day moving average of $4.12 and a two-hundred day moving average of $4.32. The firm has a market cap of $157.68 million, a P/E ratio of -2.01 and a beta of 1.07. Molecular Partners has a twelve month low of $3.41 and a twelve month high of $5.36.

Molecular Partners (NASDAQ:MOLN) last posted its earnings results on Monday, May 11th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). Equities analysts expect that Molecular Partners will post -1.32 earnings per share for the current year.

Institutional Trading of Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. SmartHarvest Portfolios LLC boosted its stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) by 26.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,543 shares of the company’s stock after buying an additional 3,232 shares during the period. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 as of its most recent filing with the Securities & Exchange Commission. 26.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MOLN. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Molecular Partners in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Molecular Partners currently has an average rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.